Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Toyota Global Sales Fall as China Demand Slumps 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Street Poller Media and The Boom of the Street Interview Ad Industry 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Add as a preferred source on Google
VANCOUVER, British Columbia, April 09, 2018 -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB) (OTCQB:RVVQF) (Frankfurt:1IT) today announced that it has secured DTC Eligibility for its common shares listed on the OTC market in the United States.
About the Depository Trust Company
The Depository Trust Company (DTC) is a subsidiary of the Depository Trust & Clearing Corporation DTCC and manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered "DTC eligible." This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.
About RavenQuest BioMed Inc.
RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
“George Robinson”
Chief Executive Officer
For further information, please contact:
Mathieu McDonald, Corporate Communications – 604-484-1230
Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
